# Syntis Bio

> Syntis Bio is a Boston clinical-stage biopharmaceutical company developing oral therapies built on SYNT, a temporary small-intestinal coating inspired by mussel adhesion. Lead candidate SYNT-101 aims to redirect nutrients and stimulate the body’s own satiety hormones; additional programs target rare metabolic disorders and improved drug delivery. The therapies remain investigational.

- **Founded:** 2022
- **Headquarters:** Boston, United States
- **Founders:** Rahul Dhanda (Co-founder, President and CEO), Robert Langer (Scientific co-founder and board director), Giovanni Traverso (Scientific co-founder, board director and Clinical Advisory Board chair)
- **Products:** SYNT platform, SYNT-101, SYNT-113, SYNT-115, SYNT-212
- **Notable:** Public company launch in June 2024 following a $15.5 million seed round., Acquired two rare-disease enzyme programs from Codexis in April 2024., Closed a $33 million Series A in July 2025.

## Products & services

- **SYNT platform** — Investigational synthetic tissue-lining technology using mussel-inspired polydopamine chemistry to create a temporary intestinal coating; applications include nutrient redirection, local enzyme retention and enhanced oral absorption.
- **SYNT-101** — Investigational daily oral obesity tablet intended to redirect nutrient absorption away from the proximal small intestine and stimulate endogenous satiety hormones. Phase 1/1b completed; Phase 2 initiation planned for 2027.
- **SYNT-113** — Preclinical obesity program pairing SYNT with a small molecule; detailed compound identity is not publicly disclosed.
- **SYNT-115** — Preclinical obesity program pairing SYNT with a biologic; detailed compound identity is not publicly disclosed.
- **SYNT-212** — Current homocystinuria program combining SYNT with a gut-restricted engineered enzyme. Historical announcements called the enzyme program SYNT-202.
- **SYNT-213** — Current maple syrup urine disease program combining SYNT with a gut-restricted engineered enzyme. Historical announcements called the enzyme program SYNT-203.

## Achievements

- Public company launch in June 2024 following a $15.5 million seed round.
- Acquired two rare-disease enzyme programs from Codexis in April 2024.
- Closed a $33 million Series A in July 2025.
- Completed Phase 1/1b SYNTIETY-1 evaluation in 55 participants.
- Reported a placebo-adjusted weight-loss signal in the 23-person, 28-day multiple-dose portion in September 2026; numerical weight-loss magnitude was not given in the release.

## Latest updates

- **2026-09** — Reported 28-day Phase 1/1b multiple-dose results: greater weight loss than placebo across three cohorts, exploratory satiety-hormone changes and no discontinuations or dose reductions; Phase 2 planned for 2027.
- **2026-07** — Reported single-dose results in 32 healthy volunteers, including delayed glucose absorption and satiety-hormone modulation; mild self-limited hypoglycemia during glucose testing was the only treatment-related adverse event reported.
- **2026-06** — Appointed Matt Dallas Chief Financial Officer.
- **2026-03** — Announced first patient dosed in SYNTIETY-1 and appointments of David Rosenbaum as Chief Development Officer and Christo Shalish as Chief Business Officer.

## Links

- Website: https://syntis.bio/
- LinkedIn: https://www.linkedin.com/company/syntis-bio/
- Twitter/X: https://x.com/syntisbio

---

Profile page: https://yespress.io/syntis-bio
Published by YesPress — https://yespress.io
Last updated: 2026-10-03